Results 51 to 60 of about 19,996 (219)

Australian trachoma surveillance report 2012 [PDF]

open access: yes, 2013
Australia is the only high income country where trachoma is endemic. It occurs primarily in remote and very remote Aboriginal communities in the Northern Territory (NT), South Australia (SA) and Western Australia (WA).

core  

Longitudinal Analysis of Antibody Responses to Trachoma Antigens Before and After Mass Drug Administration. [PDF]

open access: yes, 2014
Blinding trachoma, caused by the bacteria Chlamydia trachomatis, is a neglected tropical disease targeted for elimination by 2020. A major component of the elimination strategy is mass drug administration (MDA) with azithromycin.
Ryan E Wiegand   +21 more
core   +2 more sources

Prevalence and risk factors for trachoma in central and southern Malawi. [PDF]

open access: yesPLoS ONE, 2010
BACKGROUND: Trachoma, one of the neglected tropical diseases is suspected to be endemic in Malawi. OBJECTIVES: To determine the prevalence of trachoma and associated risk factors in central and southern Malawi.
Khumbo Kalua   +5 more
doaj   +1 more source

Community Health Workers' Multiple Understandings of Schistosomiasis Transmission Pathways: Exploring Contextual Factors in Côte d'Ivoire, Kenya and Uganda

open access: yesTropical Medicine &International Health, Volume 31, Issue 10, Page 1453-1464, October 2026.
ABSTRACT Objective Schistosomiasis remains a public health concern in sub‐Saharan Africa, affecting over 250 million people. In endemic settings, schistosomiasis transmission is not always understood exclusively in biomedical terms. Community health workers (CHWs) contribute to schistosomiasis control through mass drug administration and health ...
Dianne Verhoeven   +21 more
wiley   +1 more source

Conjunctival FOXP3 expression in trachoma: do regulatory T cells have a role in human ocular Chlamydia trachomatis infection? [PDF]

open access: yes, 2006
BACKGROUND: Trachoma, caused by ocular infection with Chlamydia trachomatis, remains the leading infectious cause of blindness and in 2002 was responsible for 3.6% of total global blindness.
Faal Nkoyo   +23 more
core   +1 more source

MAGNITUDE OF TRACHOMA IN MEDICAL CAMPS AT DARFUR, SUDAN

open access: yesPakistan Armed Forces Medical Journal, 2012
Objective: To determine the prevalence of trachoma and its potential risk factors in medical camps established by Pak Field Hospital in Darfur, Sudan. Study Design: Cross sectional descriptive study.
Lt Col Qamar Ul Islam   +3 more
doaj   +2 more sources

Transformative Pathways for Strengthening Climate‐Resilient Health Systems Among Indigenous Communities: Advancing Equity and Sustainability in Global Health

open access: yesSustainable Development, Volume 34, Issue 4, Page 5382-5396, August 2026.
ABSTRACT Most climate‐resilience health interventions are designed at the global level, with minimal attention to Indigenous communities' needs. The lack of consideration can lead to unintended harm and exacerbate health risks. This study aims to identify the capacities of Indigenous communities that can serve as transformative pathways in safely ...
Chrishma D. Perera   +17 more
wiley   +1 more source

Trachoma

open access: yesThe Lancet
Trachoma, the leading infectious cause of blindness worldwide, is one of several neglected tropical diseases targeted by WHO for elimination by 2030. The disease starts in childhood with repeated episodes of conjunctival Chlamydia trachomatis infection.
Habtamu, Esmael   +8 more
openaire   +2 more sources

Novel approaches to evaluate the impact of the SAFE strategy on trachoma and other neglected tropical diseases in Amhara National Regional State, Ethiopia [PDF]

open access: yes, 2014
Background: Trachoma, a blinding bacterial disease of the ocular surface, is the leading cause of infectious blindness, responsible for the visual impairment of 2.2 million people worldwide and an estimated economic loss of US$ 5.3 billion annually ...
King, Jonathan D.
core   +1 more source

Safety and immunogenicity of an adjuvanted human onchocerciasis vaccine candidate, OvMANE1: preclinical evaluation in a mice model

open access: yesClinical &Translational Immunology, Volume 15, Issue 7, 2026.
OvMANE1 formulated with Freund's adjuvant was safe and elicited strong humoral and cellular immune responses, including significant IgG and leukocyte activation. These findings highlight OvMANE1 as a promising multi‐epitope vaccine candidate for advancing onchocerciasis prevention.
Derrick Neba Nebangwa   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy